Agios Pharmaceuticals (AGIO) Depreciation and Depletion (2012 - 2020)

Agios Pharmaceuticals has reported Depreciation and Depletion for 9 years, with the latest figure at $2.4 million in Q2 2020.

• For the quarter ending Q2 2020, Depreciation and Depletion rose 19.39% year-over-year to $2.4 million; the trailing twelve-month figure through Jun 2020 stood at $8.9 million (up 13.96% YoY), and the FY2025 full-year result was $5.2 million, down 8.77% from the prior year.
• Depreciation and Depletion for Q2 2020 stood at $2.4 million, down from $2.5 million in the prior quarter.
• The five-year high for Depreciation and Depletion was $2.5 million in Q1 2020, with the low at $1.2 million in Q1 2016.
• Historically, Depreciation and Depletion has averaged $1.8 million across 5 years, with a median of $1.7 million in 2018.
• Annual changes were most pronounced in 2016 — Depreciation and Depletion surged 236.76% — and 2017, when it dropped 5.37%.
• Agios Pharmaceuticals' Depreciation and Depletion stood at $1.7 million in 2016, then declined by 5.37% to $1.6 million in 2017, then gained by 19.54% to $1.9 million in 2018, then retreated by 3.25% to $1.9 million in 2019, then rose by 29.64% to $2.4 million in 2020.
• The last three Depreciation and Depletion figures came in at $2.4 million (Q2 2020), $2.5 million (Q1 2020), and $1.9 million (Q4 2019), per Business Quant data.